Single-Chain Antibodies Directed to Norovirus GI.1 and GII.4 and Their Use

Vaccines and therapies to prevent and treat Norovirus infections are not available, despite the worldwide prevalence of Norovirus infections. Outbreaks of human gastroenteritis attributable to Norovirus commonly occur in group settings, such as hospitals, nursing homes, schools, dormitories, cruise ships and military barracks. This application claims isolated VHH monoclonal antibodies that specifically bind to a Norovirus polypeptide. Llama-derived single chain antibody fragments (also called VHH) are small, recombinant monoclonal antibodies of 15 kDa (“nanobodies”) with several advantages over conventional antibodies. The antibodies that were derived from llamas showed strong neutralizing activity against Norovirus in in vitro assays. These nanobodies may have application as immunoprophylaxis to protect individuals from infections or as a possible treatment for infected individuals, or can be used to develop a diagnostic for detection of norovirus infections, and may be potentially utilized in vaccine research.

Potential Commercial Applications: Competitive Advantages:
  • Therapeutics
  • Diagnostics
  • Vaccine research
  • Ease of manufacture
  • Potent neutralizing activity
  • Potential cross-reactivity
  • Low-cost therapeutics/immunoprophylaxis


Karin Bok (NIAID)  ➽ more inventions...

Stanislav Sosnovtsev (NIAID)  ➽ more inventions...

Lisbeth Kim Green (NIAID)  ➽ more inventions...

Gladys Parreno

Lorena Garaicoechea

Andrea Aguilar

Marina Bok

Intellectual Property:
US Pat: 10,000,556 issued 2018-06-19
PCT Pat: 10,662,238 issued 2020-05-26
US Application No. 14/889,774 filed on 2015-11-06
US Application No. 15/982,998 filed on 2018-05-17
US Application No. 16/854,703 filed on 2020-04-21
Various international patent applications may also be available.

Garaicoechea L, et al. PMID 26267898

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a therapeutic, diagnostic or vaccine for Norovirus infections. For collaboration opportunities, please contact Dr. Elizabeth Pitts at or 240-669-5299.

Licensing Contact:
Elizabeth Pitts,
Phone: 240-669-5299

OTT Reference No: E-136-2013-0
Updated: Feb 8, 2021